Assembly Biosciences is developing therapeutics aimed at treating serious viral diseases, including Herpes Simplex Virus.
3 reports, 1 independent
Updated Aug 8
Gone quiet
- Reports
- 3
- Developments
- 3
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Assembly Biosciences is developing therapeutics aimed at treating serious viral diseases, including Herpes Simplex Virus.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Assembly Biosciences received clearance for study expansion.Sub-event
Assembly Biosciences is developing new therapeutics for serious viral diseases.1 source
Assembly Biosciences announced data on serious viral diseases, including Herpes Simplex Virus, at the STI & HIV 2025 World Congress.1 source
Keep exploring
The entities involved
-
Assembly Biosciences (United States)
company in Carmel, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswireAssembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Le
- GlobeNewswireAssembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus – Data to date in single- and multiple-ascending dose cohor
- GlobeNewswireAssembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop – Phase 1a clinical data in healthy participan